ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 543

Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy

Stefano Alivernini1, Luca Petricca1, Laura Bui2, Barbara Tolusso1, Gabriele Di Sante1, Roberta Benvenuto2, Anna Laura Fedele1, Elisa Gremese1 and Gianfranco Ferraccioli1, 1Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Psoriatic arthritis, remission, Rheumatoid arthritis (RA), synovitis and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection criteria to define remission status reduces the disease flare rate after treatment tapering or discontinuation in RA but not in PsA patients. The aim of the study was to define the synovial features of RA and PsA patients in clinical and ultrasound remission achieved through combination therapy with Methotrexate and TNF-blockers.

Methods:  RA patients in stable remission (n=22) (DAS<1.6 for at least 6 months), RA patients in stable low disease activity (LDA) (n=8) (1.6<DAS<2.4 for at least 6 months) and PsA patients in stable remission (n=15) (DAS<1.6 and PASI=0 for at least 6 months) achieved by MTX+anti-TNF agents (Adalimumab 40mg or Etanercept 50mg) with Power Doppler (PDUS) negative Synovial Hypertrophy (SH) (confirmed twice 3 months apart) underwent synovial tissue biopsy. RA patients with high/moderate disease activity naïve to any DMARDs (n=50) were included as comparison group. Immunostaining for CD68, CD21, CD20, CD3, CD31 and Collagen was performed.

Results:  PDUS negative RA patients in remission did not differ from PDUS negative RA patients in LDA and PDUS negative PsA patients in remission for age, sex, disease duration, treatment duration and mean dose of MTX or TNF-inhibitor regimen. PDUS negative RA patients in remission showed lower histological scores for synovial CD68+ (p=0.001 for lining and sublining), CD20+ (p=0.01 for lining and p=0.03 per sublining), CD3+ (p=0.01 for lining and sublining), CD31+ vessels (p<0.001) and collagen deposition (p=0.03 for lining and p=0.01 for sublining) compared to PDUS positive RA patients naïve to treatment with high/moderate disease activity. However, PDUS negative RA patients in LDA, showed lower histological scores only for sublining CD68+ (p=0.03) and CD20+ cells (p=0.05), lining CD3+ cells (p=0.04), CD31+ vessels (p<0.001) and sublining deposition of collagen (p=0.05) compared to PDUS positive RA patients naïve to treatment with high/moderate disease activity. In addition, there was no significant difference in terms of lining and sublining CD68+, CD20+, CD3+, CD31+ cells and collagen comparing PDUS negative RA patients in remission and in LDA respectively. On the contrary, PDUS negative PsA patients in remission did show higher histological scores for sublining CD68+ (p=0.04) and CD3+ cells (p=0.04) as well as CD31+ vessels (p=0.01) than PDUS negative RA patients in remission.

Conclusion:  PDUS negative RA patients in remission have comparable synovial histological features compared to PDUS negative RA patients in LDA. However, PsA patients in remission are characterized by higher degree of residual synovial inflammation compared to RA patients in remission despite PDUS negativity after TNF-inhibition success.


Disclosure: S. Alivernini, None; L. Petricca, None; L. Bui, None; B. Tolusso, None; G. Di Sante, None; R. Benvenuto, None; A. L. Fedele, None; E. Gremese, None; G. Ferraccioli, Roche, Pfizer, Abbott, 5.

To cite this abstract in AMA style:

Alivernini S, Petricca L, Bui L, Tolusso B, Di Sante G, Benvenuto R, Fedele AL, Gremese E, Ferraccioli G. Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/synovial-features-of-rheumatoid-arthritis-and-psoriatic-arthritis-differ-in-patients-in-clinical-and-ultrasound-remission-after-anti-tnf-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-features-of-rheumatoid-arthritis-and-psoriatic-arthritis-differ-in-patients-in-clinical-and-ultrasound-remission-after-anti-tnf-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology